Scroll Top

Open Studies

ACCRF has compiled a list of clinical trials for ACC patients with progressive disease to consider. This website is updated periodically, but may not list all the pertinent and available trials. Patients may search on their own for recruiting ACC clinical trials on the ClinicalTrials.gov website.

The clinical trials are broken down into three categories.

  • The first table lists studies that are recruiting any and all ACC patients (usually phase II clinical trials).
  • The second table lists studies appropriate for ACC patients whose tumors have been profiled and found to have activating alterations in NOTCH genes (either phase I or II clinical trials).
  • The third table includes clinical trials for patients with unresectable (inoperable) or residual tumors. These typically incorporate radiation therapy.

In all cases, patients should consult with their physicians to discuss the appropriate course of action.

Not all clinical trials have similarly strong scientific rationales for why the drugs should be effective in ACC. The most promising studies will involve drugs that (1) target the known mechanisms of action that drive ACC progression, (2) demonstrate activity in preclinical models of ACC, and (3) have reports of clinical benefit in an ACC patient from a case study or Phase I clinical trial. To assist patients in appraising each clinical trial, we indicate whether the evidence supporting the scientific rationale is strong, solid or fair. This assessment is based on the underlying scientific rationale, and does not mean that a particular trial is better or worse for any given patient, and should be considered along with his or her physician.

The table below lists clinical trials that currently are recruiting ACC patients in particular or salivary gland cancer patients. Unless otherwise noted, these studies are for only ACC patients with recurrent or metastatic disease. Links are provided to descriptions of the drugs as well as the www.ClinicalTrials.gov summary of each study.

Clinical Trials for All ACC Patients
Compound TargetsSponsor Locations Scientific Rationale Info Link Contact
REM-422 MYB Remix (USA) Ann Arbor, MI,
Boston, MA,
Houston, TX,
Nashville, TN
New York, NY, USA
Strong View Barb Geiger, BSN
913-206-2798
[email protected]
TAK-676 and Pembrolizumab STING and PD-1 Takeda Boston, MA, USA Strong View Dr. Lori Wirth [email protected]
CAB-AXL-ADC BA3011 (pre-treatment biopsy required to test for AXL expression) AXL BioAtla USA, Hong Kong, Taiwan Strong View Hazel Buncab 858-263-1598 [email protected]
Ji Hwan Lee 858-286-7702 [email protected]
APG-115 MDM2 University of Michigan Ann Arbor, MI, USA Strong View Paul L Swiecicki, MD 1-734-647-1017 [email protected]
Ryan Drzewicki [email protected]
KT-253 MDM2 Kymera Boston, MA,
Houston, TX,
Scottsdale, AZ, USA
Strong View Oncology Clinical Trials Nurse Navigator
480-323-1791
[email protected]
ATRA Combinations MYB Shanghai Ninth People's Hospital Shanghai, China Strong View Guopei Zhu, MD
021-23271699 ext 5665
[email protected]
Lutetium-177-PSMA / Radioligand Therapy PSMA Peking Union Medical College Hospital Beijing, China Solid View Zhaohui Zhu, MD
86-13611093752
[email protected]
Stereotactic Body Radiation Therapy (for patients with up to 5 metastases) Oligometastases Dana Farber Boston, MA, USA Solid View Jonathan D Schoenfeld, MD, MPH
617-632-5296
[email protected]
Glenn J Hanna, MD
617-632-3090
[email protected]
Sacituzumab Govitecan (Trodelvy) TROP2 Gilead Houston, TX, USA Solid View Renata Ferrarotto, MD
[email protected]
LCB84 and anti-PD-1 monoclonal antibody (pre- and on-treatment biopsies required if deemed medically feasible and safe) TROP2 LegoChem Biosciences, Inc Boston, MA
Dallas, TX
Houson, TX
Solid View Glenn J Hanna, MD
617-632-3090
[email protected]
Douglas Orr, MD
972-566-3000
[email protected]
Anjali Raina
713-792-3238
[email protected]
OBT-076 CD205 Oxford Biotherapeutics Bordeaux, France Fair View Jean Bourhis, Pr
021 314 46 65 ext +41
[email protected]
Frédéric Rolland, Dr
0 2 40 67 99 00 ext +33
[email protected]
Pembrolizumab and Docetaxel PD-1 Immunotherapy University of Chicago Chicago, IL, USA Fair View Alexander Pearson, MD, PhD
[email protected]
Pembrolizumab and Pemetrexed PD-1 Immunotherapy Mayo Clinic Rochester, MN, USA
Scottsdale, AZ, USA
Fair View Clinical Trials Referral Office
855-776-0015
[email protected]
Amivantamab EGFR, MET U of Cincinnati Cincinnati, OH, Boston, MA, USA Fair View Christine Vollmer 513-213-3203
Glenn J Hanna, MD 617-632-3090
EGFR Tyrosine Kinase Inhibitors EGFR Qingdao Central Hospital Qingdao, Shandong, China Fair View Youxin Ji, MD
68665078
[email protected]
Implantable Microdevice for Drug Screening (not a therapy; research study for only surgical patients without prior drug treatment) Various DFCI (USA) Boston, MA, USA Not Applicable View Glenn J Hanna, MD
617-632-3090
[email protected]

Approximately 25% of metastatic ACC patients have tumors with activating alterations in the NOTCH pathway (primarily in the NOTCH1 gene). These tumors behave more aggressively. Patients for whom tumor profiling has identified a NOTCH pathway alteration may wish to discuss the following studies with their physicians:

Clinical Trials for ACC Patients with “ACC-1” Tumors

“ACC-1” tumors typically include activating NOTCH alterations, solid histology and/or low p63 expression, while “ACC-2” tumors typically do not have any of these characteristics (see Ferrarotto et. al., Clin Cancer Res, 2021). Experienced physicians can explain to patients whether they might have “ACC-1” or “ACC-2” tumors based on tumor profiling and pathology reports.

Compound TargetsSponsor Locations Scientific Rationale Info Link Contact
CB-103 and Lenvatinib or Abemaciclib NOTCH, VEGFR, CDK4/6 Cellestia Boston, MA, USA Strong View Glenn J Hanna, MD
617-632-3090
[email protected]
XMT-1660 B7H4 Mersana Boston, MA, USA Strong View Glenn J Hanna, MD
617-632-3090
[email protected]
Studies for Patients with Unresectable (Inoperable) OR RESIDUAL, Locally-Advanced Tumors
Compound Modality Sponsor Locations Info Link Contact
Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) (SANTAL) (for residual or unresectable tumors) Radiation and Systemic Therapy GORTEC Saint-Mandé, France View François Régis FERRAND, MD
+33 1 43 98 50 78
[email protected]
Juliette THARIAT, Prof
+33 06 45 53 98 01
[email protected]
Apatinib and Proton Radiation (for inoperable or residual ACC) Radiation and Systemic Therapy Shanghai Proton and Heavy Ion Center Shanghai, China View Lin Kong, MD [email protected]
Jiyi Hu, MD [email protected]
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Radiation Massachusetts General Hospital Boston, MA, USA View Annie W Chan, MD
617-724-1159
[email protected]
Carbon Ion Only Irradiation vs Boost (ACCO) Radiation Heidelberg University Heidelberg, Germany View Klaus Herfarth, Prof. Dr.
+49 6221 568201
[email protected]
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors (ETOILE) Radiation Hospices Civils de Lyon Multiple sites in France View Pascal Pommier, MD
(0)4 78 78 51 66 ext +33
[email protected]